about
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaPhenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2APreclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis.Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemiaEradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigenLiposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myelomaPreclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myelomaPHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formationCombined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells
P50
Q33403183-81B82873-D882-400A-8213-9A67CE13038EQ34454578-3D37B123-E4CF-4ACC-A104-55C38DFBFD53Q36213431-0253C770-8E3F-43D5-980D-386EC926D615Q37524180-8003796B-DFAB-4A01-BC29-58A40C6A44FFQ38153534-48F8A8DE-8E4A-4427-969C-F5E993F3141FQ38812262-2DC4EE07-8A50-497C-A37D-D7F82EA861B3Q38881386-40349D5F-97A0-4112-8D52-151E8DD717B3Q38940345-E2945C00-BF57-4ECA-94F4-32CD9C4F0083Q39028178-BDDEE851-5B0F-469A-BEB9-FD08CCEC070EQ39100301-14B4046B-0E1F-4F09-8C1E-8C70E10E1087Q39674450-5F8E8BA7-9B0F-4FC2-A6A0-FAB04448A9E1Q39766374-D9FA9F36-B9F4-4064-B9F7-3E15462FC435Q39980314-DB5910E3-7E21-42BB-924A-58CA598941DCQ40125833-81F1390B-0D4E-4D9B-A98D-1470B11502E9Q40972516-5CE7E074-0D36-4345-B8FB-B7AE10EB875AQ42391580-BD06DE0B-A2DE-4B6B-9771-E67602714132Q45345272-3528F200-C12E-4241-87BF-4A0F11AE1995Q47630577-A6089056-836C-4252-B365-3B9F8169E8C9Q49714530-3C4F43D4-B547-4160-9B94-79012C6F3E0BQ50032634-9EA2F00A-512D-4A56-9ECD-EA76C74CD5BCQ50895991-639C328C-032C-4BF0-9ABC-5F6D4FCB3150Q51353105-4F2D619E-C13B-4DB9-A8F4-135820B44AC5Q52609801-0756A3A3-94B9-4E8B-A47C-61D11A016922Q53507006-05E9F62D-B0F2-447A-A572-AD9F39F7986DQ64077464-9E6A3034-6661-4110-BF2C-58640C3F5142Q82382125-5E6988A8-4F7D-412A-98F6-51C98CD68497Q91223762-F1B8DF44-F900-4516-998E-DBECF2FE2E68Q92254015-7BB3E31F-D555-4E4D-992D-21F014702F53Q92429871-61556033-0BF6-4778-9A55-085B56DFC039Q93064537-DEB93E6D-8A95-4194-A401-E892AB6469E5
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5010-4604
@en
name
Richard W Groen
@ast
Richard W Groen
@en
Richard W Groen
@es
Richard W Groen
@nl
type
label
Richard W Groen
@ast
Richard W Groen
@en
Richard W Groen
@es
Richard W Groen
@nl
prefLabel
Richard W Groen
@ast
Richard W Groen
@en
Richard W Groen
@es
Richard W Groen
@nl
P106
P1153
11239508500
P31
P496
0000-0002-5010-4604